Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer
February 3rd 2016Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.
Read More
Dr. Mayer on Toxicities Associated With Therapies for ER+ Breast Cancer
October 6th 2015Ingrid A. Mayer, MD, associate professor of medicine, co-leader and clinical director, Breast Cancer Research Program, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses toxicities that are associated with therapies for ER-positive metastatic breast cancer.
Read More